European Journal of Hematology
Fecha de publicación: 20 october 2018
DOI: https://doi.org/10.1111/ejh.13186
Autores: Reyad Dada, Binyam Usman
Background: Relapsed cHL patients after autologous hematopoietic stem cell transplantation (HSCT) with treatment‐sensitive disease are potential candidates for curative allogeneic HSCT. However, there are some concerns around performing such procedure after checkpoint inhibitors (CPIs).